Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PORTIA
- Sponsors Novartis Pharmaceuticals
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.
- 22 Aug 2018 New trial record